Wall Street analysts expect LivaNova PLC (NASDAQ:LIVN) to announce earnings of $0.68 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for LivaNova’s earnings. The lowest EPS estimate is $0.65 and the highest is $0.70. LivaNova reported earnings per share of $0.96 during the same quarter last year, which would suggest a negative year-over-year growth rate of 29.2%. The company is expected to issue its next earnings results on Wednesday, August 7th.
According to Zacks, analysts expect that LivaNova will report full-year earnings of $2.98 per share for the current financial year, with EPS estimates ranging from $2.90 to $3.02. For the next financial year, analysts expect that the company will post earnings of $3.44 per share, with EPS estimates ranging from $3.30 to $3.53. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover LivaNova.
LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 1st. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.11. The business had revenue of $250.80 million for the quarter, compared to analyst estimates of $254.89 million. LivaNova had a positive return on equity of 9.38% and a negative net margin of 19.64%. The business’s quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the company posted $0.68 EPS.
Several research analysts have commented on the company. Stifel Nicolaus reissued a “buy” rating and issued a $100.00 price objective on shares of LivaNova in a research report on Friday, April 5th. Needham & Company LLC reissued a “buy” rating and issued a $100.00 price objective on shares of LivaNova in a research report on Tuesday, April 9th. BidaskClub raised LivaNova from a “hold” rating to a “buy” rating in a research report on Wednesday, February 20th. BTIG Research reissued a “hold” rating on shares of LivaNova in a research report on Tuesday, March 5th. Finally, ValuEngine lowered LivaNova from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $106.40.
In other news, Director Alfred J. Novak sold 1,300 shares of the firm’s stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $70.63, for a total transaction of $91,819.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William A. Kozy bought 1,000 shares of the stock in a transaction dated Thursday, May 2nd. The shares were acquired at an average price of $72.81 per share, with a total value of $72,810.00. The disclosure for this purchase can be found here. Company insiders own 0.41% of the company’s stock.
Several institutional investors have recently made changes to their positions in LIVN. Teachers Advisors LLC grew its stake in shares of LivaNova by 96.1% during the 3rd quarter. Teachers Advisors LLC now owns 206,592 shares of the company’s stock valued at $25,611,000 after acquiring an additional 101,262 shares during the period. Vanguard Group Inc. grew its stake in shares of LivaNova by 6.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,083,237 shares of the company’s stock valued at $134,289,000 after acquiring an additional 68,637 shares during the period. Meeder Asset Management Inc. grew its stake in shares of LivaNova by 130.8% during the 4th quarter. Meeder Asset Management Inc. now owns 1,632 shares of the company’s stock valued at $148,000 after acquiring an additional 925 shares during the period. Mitsubishi UFJ Asset Management UK Ltd. lifted its holdings in LivaNova by 70.0% in the 4th quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 17,000 shares of the company’s stock worth $1,555,000 after purchasing an additional 7,000 shares in the last quarter. Finally, Bank of Montreal Can lifted its holdings in LivaNova by 6.7% in the 4th quarter. Bank of Montreal Can now owns 4,744 shares of the company’s stock worth $434,000 after purchasing an additional 297 shares in the last quarter. Institutional investors own 88.52% of the company’s stock.
Shares of LIVN traded down $1.19 during trading hours on Friday, hitting $71.88. The stock had a trading volume of 307,061 shares, compared to its average volume of 654,434. The company has a current ratio of 0.87, a quick ratio of 0.61 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $3.55 billion, a P/E ratio of 22.68, a price-to-earnings-growth ratio of 3.14 and a beta of 0.71. LivaNova has a 12-month low of $64.80 and a 12-month high of $131.54.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
See Also: Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.